Adagene (ADAG) announced that the first patient has been dosed in its randomized, open label Phase 2 study of muzastotug in combination with Merck’s (MRK) anti-PD-1 therapy, KEYTRUDA in patients with microsatellite stable colorectal cancer, MSS CRC, with no liver metastases. The Phase 2 primary endpoint is overall response rate, ORR.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Tempest Therapeutics and Adagene’s Promising Advances in Liver Cancer Treatment
- Adagene’s Innovative Cancer Study: A Potential Game-Changer in Oncology
- Adagene initiated with a Buy at Lucid Capital
- Adagene expands SAFEbody collaboration, license agreement with Exelixis
- Adagene appoints Hoos as Executive Advisor